KMT2A and acute myeloid leukemia: A comparison of the 88 KMT2A/MLL-R+ pediatric AML cases with 47 FLT3-ITD+ pediatric AML cases showed 31 differentially expressed probesets, of which 24 probesets were significantly upregulated in pediatric KMT2A/MLL-R+ cases.